Regulus Therapeutics (RGLS) Tops Q1 EPS by 10c

Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.15), $0.10 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Aristocrat Leisure (ALL:AU) (ARLUF) PT Raised to AUD66 at RBC Capital
• Magnolia Said In Lead To Acquire Wildfire For Over $4 Billion - Bloomberg
• MakeMyTrip (MMYT) PT Raised to $84 at Goldman Sachs